CONMED Corporation (CNMD) exhibits 54.6% gross margins and 7.8% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 11.4x enterprise multiple and 4.8% implied options volatility.
Sustained 54.6% gross profitability converts into 7.5% operating margin and 7.8% ROIC, outpacing sector cost of capital.
ROIC: 7.8% // GM: 54.6%YoY revenue trajectory of +5.2% paired with 11.07% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.2% // FCF YLD: 11.07%Altman Z-Score of 1.91 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.91 // F-SCORE: 7/9Trading at 28.9x trailing P/E (26.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 28.9x // EV/EBITDA: 11.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $45.72 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend 3.4% net margins.
NET MARGIN: 3.4% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CNMD & activate live FRED threshold breach alerts.